Key result
Higher myocardial 18FDG uptake after doxorubicin is linked to ~7% lower LVEF at follow-up.
Why the study?
Does increased myocardial 18-fluorodeoxyglucose uptake predict left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with doxorubicin?
Population
43 adult patients with Hodgkin lymphoma receiving first-line doxorubicin-containing chemotherapy, without…
Design
Cohort
Follow-up
22 ± 17 months after chemotherapy completion
Authors
Loading...
May support metabolic surveillance in DOX-treated HL survivors; leaves open whether targeting glucose metabolism alters HF risk.
Cohort (n=43)
Blinded assessors
No
Does increased myocardial 18-fluorodeoxyglucose uptake predict left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with doxorubicin?
Absolute Event Rate: 65.6% vs 72.2%
p-value: p=0.04
Increased myocardial 18-FDG uptake during doxorubicin chemotherapy is associated with a subsequent decline in left ventricular ejection fraction, suggesting a potential early imaging marker for cardiotoxicity.
Sarocchi et al. (2018) conducted a cohort in Hodgkin lymphoma (n=43). High myocardial 18FDG uptake vs. Low myocardial 18FDG uptake was evaluated on Left ventricular ejection fraction at follow-up (p=0.04). In patients with Hodgkin lymphoma treated with doxorubicin, higher myocardial 18FDG uptake at the end of treatment was associated with a significantly lower left ventricular ejection fraction at follow-up (65.6% vs. 72.2%, p=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: